

## **Zydus announces settlement with Aptalis on CANASA<sup>®</sup> (mesalamine suppository, 1 g)**

---

*Ahmedabad, India, August 14, 2017*

Cadila Healthcare Limited, a global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, today announced that the patent litigation relating to Aptalis's CANASA<sup>®</sup> (mesalamine suppository, 1 g) has been settled.

As a result of the settlement, its US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of CANASA<sup>®</sup> in the United States beginning on June 13, 2019, or earlier under certain circumstances.

Zydus Cadila previously received tentative approval from the USFDA to market its generic version of CANASA<sup>®</sup> (mesalamine suppository, 1 g). CANASA<sup>®</sup> is indicated to treat mildly to moderately active ulcerative colitis. Zydus Cadila's generic product will be produced at the group's Topical plant at Ahmedabad.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 20000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*